Northwestern University, Feinberg School of Medicine, Department of Medicine, United States of America.
California Health Sciences University, College of Pharmacy, United States of America.
Biochim Biophys Acta Rev Cancer. 2022 May;1877(3):188732. doi: 10.1016/j.bbcan.2022.188732. Epub 2022 Apr 26.
Despite recent advances in the treatment landscape for prostate cancer, many challenges still remain. A more profound understanding of prostate cancer pathogenesis and the underlying mechanisms is critical to developing novel therapeutics strategies. Extracellular nucleotides play a central role in the growth and progression of a variety of cancer types - almost all tumor cells and immune cells express purinergic membrane receptors for extracellular nucleotides (ATP, ADP, UTP, UDP, UDP-sugar) and their metabolic nucleoside products (e.g., adenosine). Herein we review the pathological and immunomodulatory roles of P2Y purinergic nucleotide receptors in prostate cancer and their potential as therapeutic targets to address some of the clinical limitations in prostate cancer treatment.
尽管前列腺癌的治疗领域最近取得了进展，但仍存在许多挑战。更深入地了解前列腺癌的发病机制和潜在机制对于开发新的治疗策略至关重要。细胞外核苷酸在多种癌症类型的生长和进展中发挥着核心作用-几乎所有肿瘤细胞和免疫细胞都表达细胞外核苷酸（ATP、ADP、UTP、UDP、UDP-糖）和它们的代谢核苷产物（例如，腺苷）的嘌呤能膜受体。本文综述了 P2Y 嘌呤能核苷酸受体在前列腺癌中的病理和免疫调节作用及其作为治疗靶点的潜力，以解决前列腺癌治疗中的一些临床局限性。
